MiNK Therapeutics, Inc. filings document a clinical-stage biopharmaceutical company focused on allogeneic iNKT cell therapies, including formal disclosures about agenT-797, program updates, operating results and financing activity. Current reports have covered quarterly and annual financial results, clinical and publication-related updates, potential strategic discussions, and an at-the-market common stock sales agreement registered under a shelf registration statement.
The company’s proxy and governance filings disclose annual meeting matters, director elections, auditor ratification, board appointments, officer designations and compensation-related items. Other filings describe its Nasdaq-listed common stock, equity incentive plan activity, intercompany services arrangements with Agenus for finance functions, and risk-sensitive updates related to clinical development, capital needs and public-company governance.
MiNK Therapeutics, Inc. reported a net loss of $2.7 million for the three months ended March 31, 2026, similar to the prior-year period. Research and development expense was $1.2 million while general and administrative expense rose to $1.7 million, mainly from higher share-based compensation and professional fees.
Cash and cash equivalents were $9.5 million as of March 31, 2026, and the company has an accumulated deficit of $159.4 million. It raised about $3.0 million via at-the-market stock sales in the quarter and an additional $150,000 afterward, and repaid a $5.0 million related-party convertible note in January 2026. Management states that while existing cash plus anticipated funding are expected to cover more than one year of liquidity needs, completion of funding is not fully within its control, so substantial doubt exists about its ability to continue as a going concern.
MiNK Therapeutics, Inc. reported first quarter 2026 financial results and highlighted progress advancing its allo-iNKT cell therapy platform. The company initiated a randomized Phase 2 trial of lead candidate agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026.
MiNK ended the quarter with approximately $9.5 million in cash and cash equivalents, down from about $13.4 million as of December 31, 2025. It repaid roughly $5.2 million related to an Agenus convertible note and raised about $3.0 million via its at-the-market sales agreement. Net loss was approximately $2.7 million, or $0.57 per share, versus about $2.8 million, or $0.70 per share, a year earlier.
MiNK Therapeutics is holding its 2026 Annual Meeting virtually on June 17, 2026 at 9:30 a.m. Eastern via live audio webcast. Stockholders of record on April 23, 2026, when 4,981,899 shares were outstanding, are entitled to vote.
Investors will vote on electing three Class II directors — Garo Armen, Barbara Ryan and John Holcomb — to three-year terms expiring at the 2029 meeting, and on ratifying KPMG LLP as independent auditor for the fiscal year ending December 31, 2026. The board recommends voting FOR both proposals.
The filing details MiNK’s governance structure, committee memberships and director independence, and describes executive pay. In 2025, CEO Jennifer Buell received $448,000 in salary, a $350,000 stock-settled bonus and option grants with grant-date fair value of $1,284,195, for total compensation of $2,087,881, along with change‑in‑control and severance protections.
MiNK Therapeutics director John Bradley Holcomb received a grant of stock options covering 4,174 shares of common stock. The options have an exercise price of $14.92 per share and were awarded under the MiNK Therapeutics Inc. 2021 Amended and Restated Equity Incentive Plan. They vest in three equal annual installments on September 23, 2026, 2027 and 2028, as long as Dr. Holcomb continues his service relationship with the company. Following this grant, he holds 4,174 options directly.
MiNK Therapeutics, Inc. Principal Financial Officer Melissa Orilall filed an initial Form 3 showing an existing indirect holding of common stock. The filing reports beneficial ownership of 222 shares held indirectly through her spouse, with no new buy or sell transaction disclosed.
MiNK Therapeutics filed its annual report detailing progress on its allogeneic invariant natural killer T (iNKT) cell therapy platform, led by agenT‑797 in Phase 2 trials for cancer, severe pneumonia-related respiratory failure, and graft-versus-host disease. The company is also advancing engineered CAR‑iNKT programs MiNK‑215 and MiNK‑413 and expanding collaborations to support TCR and RNA technologies. MiNK reported a net loss of $12.5 million for 2025, compared with $10.8 million in 2024, and an accumulated deficit of $156.7 million. As of June 30, 2025, non‑affiliate market value of common stock was $10.9 million, with 4,965,858 shares outstanding as of March 27, 2026, and 15 full‑time employees as of February 28, 2026.
MiNK Therapeutics reported a net loss of $2.6 million, or $0.56 per share, for Q4 2025, versus $2.5 million, or $0.62 per share, in Q4 2024. For full-year 2025, net loss was $12.5 million, or $2.93 per share, compared with $10.8 million, or $2.86 per share, in 2024.
The company ended 2025 with $13.4 million in cash and subsequently raised an additional $3.0 million via an at-the-market program, supporting operations through 2026. MiNK highlighted non-dilutive funding, advancing Phase 2 programs in ARDS and GVHD, and multiple 2026 clinical and scientific catalysts.
MiNK Therapeutics used this report to clarify market speculation about its cell therapy candidate agenT-797. The company states it is in active discussions with multiple parties about potential combination clinical trials for agenT-797 and about possible strategic minority investments in the company.
MiNK emphasizes that these talks reflect outside interest in its allogeneic iNKT cell platform, including for serious conditions such as critical illness, but also makes clear that it has not entered into any binding agreements for trials or investments. Any such deals remain uncertain and subject to risk, as highlighted in its previously filed risk factor disclosures.
MiNK Therapeutics, Inc. filed an initial ownership report for Principal Accounting Officer Austin Charette. The filing shows beneficial ownership of 40 shares of MiNK Therapeutics common stock held directly, with no specific buy or sell transaction reported.